Gilead reassures with CAR-T therapy durability data – Leading US biotech and investment company favourite Gilead Sciences has reassured investors with an important clinical trial update for its high profile cancer therapy Yescarta, which was obtained via the $12bn purchase of Kite Pharmaceuticals earlier this year. Longer follow-up data from 108 advanced lymphoma patients treated with Yescarta […]
Gilead acquires Cell Design Labs to bolster CAR-T presence Leading US biotech Gilead Sciences is to acquire privately-held Cell Design Labs in a structured buy out valued at to $567m, including the 12.2% shareholding it already holds as a result of its $12bn acquisition of Kite Pharmaceuticals earlier this year. The Kite deal propelled Gilead […]
Alexion stock rises on reports of activist investor – Stock in the US rare disease specialist Alexion Pharmaceuticals is up 6% this morning on reports that the famed New York-based activist hedge fund Elliot Management has taken a stake. Elliott has reportedly threatened to initiate a proxy battle potentially to replace the relatively new management team […]
For fourteen consecutive years BlackRock Smaller Companies has outperformed its benchmark and increased its dividend. Over that period, the NAV has grown nearly ten-fold whereas the benchmark has almost quadrupled. The compound annual increase in dividends paid over the past five years has been 20% per annum. During the year to 28 February 2017, the NAV increased […]
Pacific Horizon (PHI), managed by Ewan Markson-Brown (pictured), has announced its interim results for the six months ended 31 January 2017. During the period, the Trust’s NAV total return was 9.7%. The share price total return was 8.0% as the discount widened from 10.1% to 11.4%. The Trust says that, over the same period the […]
Woodford Patient Capital says its portfolio declined in value by 10.8 per cent over the first half of 2016 and the company’s shares ended the period at a modest discount of 3.1 per cent. Two new non-executive directors have been brought onto the Board following consultation with shareholders. The new non-executive directors have specific investment trust experience. […]
The Board of Kuala Innovations Limited has announced that it has subscribed for a 3.5 per cent. interest in Delaware incorporated private company Intensity Therapeutics, Inc. The Company has subscribed for 250,000 Preferred Series A Shares of Intensity Therapeutics (“Subscription Shares”) at a price of US$2.00 per Subscription Share, for total cash consideration of US$500,000. […]
JPMorgan Japan Smaller Companies has announced that, for the year ended 31 March 2015, the total return on net assets was 30.9%, well ahead of the return of the Company’s benchmark, the S&P/Citigroup Japan Extended Market Index, which rose by 22.4%. Over the same period, the Company’s share price increased by 35.9%, reflecting a narrowing of the discount […]
